- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Presentation and Risk Factors
Toby Maher, MD, PhD, discusses how common signs and symptoms of idiopathic pulmonary fibrosis (IPF) at diagnosis can indicate disease progression, while also identifying key risk factors associated with IPF and emphasizing the importance of modifying certain lifestyle factors to help prevent the disease.
EP: 1.Emerging Agents in IPF Treatment
EP: 2.IPF and PDE4B Inhibitors
EP: 3.Importance of Patient-Reported Outcomes
EP: 4.Future Possibilities in IPF Treatment
EP: 5.Advice for Clinicians Treating IPF
EP: 6.Current Standard of Care in IPF
EP: 7.Therapeutic Response and Disease Progression
EP: 8.Key Considerations for Selecting IPF Treatment
EP: 9.Economic Impact of IPF
EP: 10.Unmet Needs in IPF Landscape
EP: 11.Overview of Idiopathic Pulmonary Fibrosis (IPF)
EP: 12.Impact of IPF on Quality of Life and Financial Considerations
EP: 13.Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection
EP: 14.Clinical Presentation and Risk Factors
EP: 15.Impact of Comorbidities on IPF Management
EP: 16.Overcoming Treatment Barriers: Strategies for Success
Video content above is prompted by the following:
- What signs and symptoms of IPF are often present at diagnosis, and what patient characteristics at the time of diagnosis may be predictive of disease progression?
- What risk factors are associated with IPF, and what changes can be made to modifiable risk factors to prevent the disease?
With Hidradenitis Suppurativa, Maternal and Offspring Outcomes May Suffer
October 31st 2024Novel evidence has emerged from a 16-year study that hidradenitis suppurativa can elevate risks of not only pregnancy and postpartum complications, but of morbidity—particularly metabolic- and immunology-related morbidity—for mother and child in the long term.
Read More
Low Pulmonary Rehabilitation, Palliative Care Referrals for Patients With IPF Persist
October 30th 2024Despite proven benefits, referrals to pulmonary rehabilitation and palliative care for patients with idiopathic pulmonary fibrosis (IPF) in England remain significantly lower than for other respiratory conditions.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL
October 30th 2024The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More
